case_images: PMC7098965_01
case_images: G-banding analysis of the BM sample at relapse, which showed the balanced translocation t(8;17)(q12;p11.2). (B) FISH with a chromosome 17 centromere probe (green) and a TP53 probe (red) showed one of the TP53 signals on the der chromosome, suggesting that the chromosome 17p breakpoint is centromeric to TP53 on 17p13. (C) RT-PCR showed various levels of NCOR1-LYN fusion transcript in bone marrow specimens. Lane 1: relapse sample; lane 2: 2 weeks after dasatinib; lane 3: 1 month post allo-HSCT; lane 4: 2 months post allo-HSCT; lane 5: 3 months post allo-HSCT; lane 6: 10 months post allo-HSCT; lane 7: negative control. (D) Sanger sequencing result of the NCOR1-LYN fusion gene, confirming a fusion between exon 34 of NCOR1 and exon 8 of LYN. (E) Schematic representation of the predicted domain structure of the NCOR1-LYN fusion.
case_images: fonc-10-00359-g0001.jpg
case_images: PMC7098965_02_fonc-10-00359-g0001.jpg
case_images: F1
case_images: RT-PCR assays showed significantly decreased fusion transcript (Figure 1C). He has been tolerated with dasatinib very well and remained in MRD negative remission for 10 months now post allo-HSCT, based on both flow cytometry and RT-PCR assays (Figure 1C). Timeline of the treatment was shown in Supplementary Figure 1.
case_images: NGS analysis of the bone marrow sample at relapse showed deletions of CDKN2A and IKZF1. (B,C) Bone marrow smears before and after dasatinib therapy.
case_images: fonc-10-00359-g0002.jpg
case_images: PMC7098965_02_fonc-10-00359-g0002.jpg
case_images: F2
case_images: After completion of chemotherapy, bone marrow morphology still showed 61.5% of blasts (Figure 2B). Two weeks after dasatinib treatment, bone marrow aspirates showed only 1% of blasts by histology (Figure 2C) and 0.1% of blasts by flow cytometry.
case_images: PMC7098965_02
case_images: G-banding analysis of the BM sample at relapse, which showed the balanced translocation t(8;17)(q12;p11.2). (B) FISH with a chromosome 17 centromere probe (green) and a TP53 probe (red) showed one of the TP53 signals on the der chromosome, suggesting that the chromosome 17p breakpoint is centromeric to TP53 on 17p13. (C) RT-PCR showed various levels of NCOR1-LYN fusion transcript in bone marrow specimens. Lane 1: relapse sample; lane 2: 2 weeks after dasatinib; lane 3: 1 month post allo-HSCT; lane 4: 2 months post allo-HSCT; lane 5: 3 months post allo-HSCT; lane 6: 10 months post allo-HSCT; lane 7: negative control. (D) Sanger sequencing result of the NCOR1-LYN fusion gene, confirming a fusion between exon 34 of NCOR1 and exon 8 of LYN. (E) Schematic representation of the predicted domain structure of the NCOR1-LYN fusion.
case_images: fonc-10-00359-g0001.jpg
case_images: PMC7098965_02_fonc-10-00359-g0001.jpg
case_images: F1
case_images: RT-PCR assays showed significantly decreased fusion transcript (Figure 1C). He has been tolerated with dasatinib very well and remained in MRD negative remission for 10 months now post allo-HSCT, based on both flow cytometry and RT-PCR assays (Figure 1C). Timeline of the treatment was shown in Supplementary Figure 1.
case_images: NGS analysis of the bone marrow sample at relapse showed deletions of CDKN2A and IKZF1. (B,C) Bone marrow smears before and after dasatinib therapy.
case_images: fonc-10-00359-g0002.jpg
case_images: PMC7098965_02_fonc-10-00359-g0002.jpg
case_images: F2
case_images: After completion of chemotherapy, bone marrow morphology still showed 61.5% of blasts (Figure 2B). Two weeks after dasatinib treatment, bone marrow aspirates showed only 1% of blasts by histology (Figure 2C) and 0.1% of blasts by flow cytometry.